舒尼替尼治疗转移性进展性嗜铬细胞瘤和副神经节瘤:FIRSTMAPPP 学术性、多中心、国际、随机、安慰剂对照、双盲、2 期试验结果
FIRSTMAPPP 是在 4 个欧洲国家 14 个学术中心开展的多中心、国际、随机、安慰剂对照、双盲 2 期试验,纳入 78 例成人散发性或遗传性进展性转移性嗜铬细胞瘤和副神经节瘤患者,按 1:1 随机接受口服舒尼替尼 37.5 mg/日或安慰剂,按 SDHB 状态和既往系统治疗线数分层。主要终点为实时中心审查(RECIST 1.1)的 12 个月无进展生存率,舒尼替尼组 14/39 例(36%,90% CI 23–50)vs 安慰剂组 7/39 例(19%,90% CI 11–31),达到研究设计假设(从 20% 提高到 40%)。最常见的 3 或 4 级不良事件为乏力、高血压和背痛或骨痛。作者认为该首个随机试验支持舒尼替尼作为进展性转移性嗜铬细胞瘤和副神经节瘤抗肿瘤疗效证据等级最高的药物治疗选择。
要点
- 舒尼替尼组 12 个月无进展生存率为 36%(14/39,90% CI 23–50),安慰剂组为 19%(7/39,90% CI 11–31)。
- 舒尼替尼组 3 或 4 级乏力 7/39(18%),安慰剂组 1/39(3%);3 或 4 级高血压舒尼替尼组 5/39(13%),安慰剂组 4/39(10%)。
- 舒尼替尼组发生 3 例死亡(呼吸功能不全、肌萎缩侧索硬化、直肠出血),仅直肠出血被认为与药物相关。
- 安慰剂组发生 2 例死亡(吸入性肺炎、感染性休克)。
- 作者认为该首个随机试验支持舒尼替尼作为进展性转移性嗜铬细胞瘤和副神经节瘤抗肿瘤疗效证据等级最高的药物治疗选择。
适用人群与场景
- 成人(年龄 ≥18 岁)散发性或遗传性进展性转移性嗜铬细胞瘤和副神经节瘤患者。
- 研究在 4 个欧洲国家的 14 个学术中心开展。
诊断标准与关键阈值
- 主要终点为实时中心审查(RECIST 1.1)的 12 个月无进展生存率。
处置流程与药物剂量
- 口服舒尼替尼 37.5 mg/日,随机 1:1 分配至舒尼替尼组或安慰剂组。
- 随机化按 SDHB 状态(突变存在 vs 野生型)和既往系统治疗线数(0 vs ≥1)分层。
- 允许安慰剂组交叉。
研究设计与关键结果
- FIRSTMAPPP 为多中心、国际、随机、安慰剂对照、双盲 2 期试验,2011 年 12 月 1 日至 2019 年 1 月 31 日纳入 78 例患者(每组 39 例),25/78(32%)有胚系 SDHx 变异,54/78(69%)既往接受过治疗。
- 主要终点达到:舒尼替尼组 12 个月无进展生存 14/39(36%,90% CI 23–50),安慰剂组 7/39(19%,90% CI 11–31)。
- 最常见 3 或 4 级不良事件:乏力舒尼替尼组 7/39(18%)vs 安慰剂组 1/39(3%);高血压 5/39(13%)vs 4/39(10%);背痛或骨痛 1/39(3%)vs 3/39(8%)。
- 舒尼替尼组 3 例死亡(呼吸功能不全、肌萎缩侧索硬化、直肠出血),仅直肠出血被认为与药物相关;安慰剂组 2 例死亡(吸入性肺炎、感染性休克)。
证据类型、等级与局限
- 证据类型:多中心、国际、随机、安慰剂对照、双盲 2 期试验。
- 研究设计基于两步 Simon 模型,假设 12 个月无进展生存率从 20% 提高到 40%,计划入组 78 例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该首个随机试验支持舒尼替尼作为进展性转移性嗜铬细胞瘤和副神经节瘤抗肿瘤疗效证据等级最高的药物治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested beneficial effects of sunitinib. We aimed to evaluate the safety and efficacy of sunitinib in patients with metastatic phaeochromocytomas and paragangliomas.
METHODS: FIRSTMAPPP is a multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial done at 14 academic centres across four European countries. Eligible participants were adults (aged ≥18 years) with sporadic or inherited progressive metastatic phaeochromocytomas and paragangliomas. Patients were randomly assigned (1:1) to receive either oral sunitinib (37·5 mg per day) or placebo. Randomisation was stratified according to SDHB status (mutation present vs wild type) and number of previous systemic therapies (0 vs ≥1). Primary endpoint was the rate of progression-free survival at 12 months according to real-time central review (Response Evaluation Criteria in Solid Tumours version 1.1). On the basis of a two-step Simon model, we aimed for the accrual of 78 patients, assuming a 20% improvement of the 12-month progression-free survival rate from 20% to 40%, to conclude that sunitinib is effective. Crossover from the placebo group was allowed. This trial is registered with ClinicalTrials.gov, number NCT01371201, and is closed for enrolment.
FINDINGS: From Dec 1, 2011, to Jan 31, 2019, a total of 78 patients with progressive metastatic phaeochromocytomas and paragangliomas were enrolled (39 patients per group). 25 (32%) of 78 patients had germline SDHx variants and 54 (69%) had used previous therapies. The primary endpoint was met, with a 12-month progression-free survival in 14 of 39 patients (36% [90% CI 23-50]) in the sunitinib group. In the placebo group, the 12-month progression-free survival in seven of 39 patients was 19% (90% CI 11-31), validating the hypotheses of our study design. The most frequent grade 3 or 4 adverse events were asthenia (seven [18%] of 39 and one [3%] of 39), hypertension (five [13%] and four [10%]), and back or bone pain (one [3%] and three [8%]) in the sunitinib and placebo groups, respectively. Three deaths occurred in the sunitinib group: these deaths were due to respiratory insufficiency, amyotrophic lateral sclerosis, and rectal bleeding. Only the latter event was considered drug related. Two deaths occurred in the placebo group due to aspiration pneumonia and septic shock.
INTERPRETATION: This first randomised trial supports the use of sunitinib as the medical option with the highest level of evidence for anti-tumour efficacy in progressive metastatic phaeochromocytomas and paragangliomas.
FUNDING: French Ministry of Health, through the National Institute for Cancer, German Ministry of Education and Research, and the German Research Foundation within the CRC/Transregio 205/2, EU Seventh Framework Programme, and a private donator grant.
参考来源
- Baudin E, Goichot B, Berruti A, et al. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet. 2024. PMID: 38402886. doi:10.1016/S0140-6736(23)02554-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。